Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy

By Huang Zhao-Hui   Hua Dong   Du Xiang  

Cancer Chemotherapy and Pharmacology, Vol. 64, Iss. 5, 2009-10 ,pp. : 1001-1007

Springer Publishing Company

Access to resources Recommend Favorite

Polymorphisms of GSTP1, ERCC2 and TS3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients

By                  

Oncology Letters, Vol. 6, Iss. 3, 2013-01 ,pp. : 648-654

Spandidos Publications

Access to resources Recommend Favorite

The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatinbased adjuvant chemotherapy

By                

Oncology Letters, Vol. 5, Iss. 3, 2013-01 ,pp. : 935-942

Spandidos Publications

Access to resources Recommend Favorite

Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy

By            

Molecular Medicine Reports, Vol. 7, Iss. 2, 2013-01 ,pp. : 613-617

Spandidos Publications

Access to resources Recommend Favorite

CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

By Petrioli Roberto   Licchetta Antonella   Roviello Giandomenico   Pascucci Alessandra   Francini Edoardo   Bargagli Gianluca   Conca Raffaele   Miano Salvatora Tindara   Marzocca Giuseppe   Francini Guido    

Cancer Investigation, Vol. 30, Iss. 1, 2012-01 ,pp. : 65-71

Informa Healthcare

Access to resources Recommend Favorite